WAVEMAN · COMPANY

PACB · Pacific Biosciences Of California, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

PACB

Name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

MEDICAL DEVICES · LABORATORY ANALYTICAL INSTRUMENTS · CIK 0001299130

FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$151.2K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+3.9%

XBRL, annual

NET MARGIN

-341.5%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$151.2K over 180 days

-$30.4K over 90 days

more than 55% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

94 funds added or opened last quarter

more than 56% of Medical Devices

REVENUE

+3.9% year over year

below 63% of Medical Devices

MARGIN

-341.5% net margin

below 91% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

15.8% of shares outstanding short · 7.3 days to cover · settled 2026-07-31

more than 96% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

94 funds added or opened positions in the latest 13F quarter, of 223 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +1.6%

+1.6%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $151.2K sold by insiders over 180 days, 94 funds added last quarter, $30.5K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. insiders sold a net $151.2K of stock across 66 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Van Oene Mark

See Remarks

SELL

2026-08-17

26,911.0

$30.4K

Gibson James R II

See Remarks

SELL

2026-04-01

88,185.0

$120.8K

HENRY CHRISTIAN O

See Remarks

SELL

2026-03-03

12,497.0

$18.9K

Van Oene Mark

See Remarks

SELL

2026-03-03

6,504.0

$9.8K

Farmer Michele

See Remarks

SELL

2026-03-03

2,979.0

$4.5K

66 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 61 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

32,339,550.0 sh

$54.3M

ARK Investment Management LLC

29,781,416.0 sh

$50.0M

SOFTBANK GROUP CORP.

20,451,570.0 sh

$34.4M

VANGUARD CAPITAL MANAGEMENT LLC

13,397,934.0 sh

$22.5M

GEODE CAPITAL MANAGEMENT, LLC

7,606,518.0 sh

$12.8M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

MARK VAN OENE

FILED 2026-08-17

$30.5K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

ARK Genomic Revolution ETF

$17.4M POSITION · AS OF 2026-04-30

1.4%

AltShares Event-Driven ETF

$76.4K POSITION · AS OF 2026-02-28

0.7%

Water Island Event-Driven Fund

$260.4K POSITION · AS OF 2026-02-28

0.5%

American Beacon ARK Transformational Innovation Fund

$760.0K POSITION · AS OF 2026-03-31

0.5%

iShares Genomics Immunology and Healthcare ETF

$768.0K POSITION · AS OF 2026-04-30

0.5%

Global X Genomics & Biotechnology ETF

$200.8K POSITION · AS OF 2026-02-28

0.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$160.0M	$154.0M	$200.5M	$128.3M
GROSS PROFIT	$45.8M	$37.3M	$52.8M	$49.0M
OPERATING INCOME	$-553.9M	$-474.3M	$-334.5M	$-307.2M
NET INCOME	$-546.4M	$-309.9M	$-306.7M	$-314.2M
EPS (DILUTED)	-1.82	-1.59	-1.21	-1.40
OPERATING CASH FLOW	$-111.2M	$-206.1M	$-259.2M	$-263.2M
CASH	$63.7M	$55.4M	$179.9M	$325.1M
LONG-TERM DEBT	—	—	—	$896.7M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE